Xunda Pharmaceutical
Wuxue
About Xunda Pharmaceutical
Hubei Xunda Pharmaceutical Co., Ltd. (Φ┐àΦ╛╛Φì»Σ╕Ü) is a modern Chinese pharmaceutical enterprise that produces anti-inflammatory and analgesic drugs, and bulk pharmaceutical chemicals for antibiotics and pharmaceutical intermediates. Hubei Xunda Pharmaceutical’s main product portfolio includes ketoprofen, felbinac, fosfomycin calcium, fosfomycin sodium, fosfomycin trometamol, cyano ketone ibuprofen, loxoprofen sodium, and more. These products have been sold to countries and regions such as Japan, Korea, the Middle East, Europe, and America. The company owns advanced production equipment, complete testing equipment, technical forces, scientific and standard management solutions, and a number of invention patents. Hubei Xunda Pharmaceutical has gotten through the Chinese GMP certification and official GMP on-site audit of JMHW, while its ketoprofen product has obtained the European COS certificate.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $2.4M
- Funding stage: Early Stage Venture
- Last round: Series B (Aug 2011)
- Website: xundapharm.com
- Phone: 86 71 3621 2945
Industries & Categories
Biotechnology, Chemical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/xunda-pharmaceutical-412235 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.